Researchers from UNICAMP used functional magnetic resonance imaging to assess 86 volunteers who had moderate COVID-19 and compared the results with those of uninfected volunteers. Preliminary findings have not yet been published but were presented during the 7th BRAINN Congress.
A study performed at BRAINN resulted in development of a novel rehabilitation device. The article was recognized as outstanding by the 20th International Conference on Computational Science and its Applications.
Study identifies 306 genetic variants linked to brain structure and predisposition to certain diseases
Researchers from ENIGMA, an international consortium to which BRAINN is affiliated with, measured cortical volume in 51,665 participants based on quantitative MRI and correlated the data with genetic markers.
An analysis performed with 264 people living in and around Campinas mapped 900,000 genetic markers distributed in their genomes. This research was conducted under the aegis of BRAINN with the goal of laying foundations for precision medicine and provide input for public health policy.
Implantable devices now being tested were developed in Australia and could improve the quality of patients’ lives. These novel devices were presented to the congress of BRAINN.
Studies conducted at BRAINN and part of international consortia are able to identify better treatments for diseases such as epilepsy, cerebral vascular accident and amyotrophic lateral sclerosis.
Study suggests dysregulation of gene NEUROG2 could be linked to development of focal cortical dysplasia, one of the most common causes of drug-resistant epilepsy
A multicenter study involving BRAINN, a research center funded by FAPESP, analyzed the brains of over 3,800 volunteers in search of anatomical alterations specific to each epilepsy subtype